Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Efficacy and Safety of Brinzolamide 1%/Timolol 0.5% Fixed Combination Versus Dorzolamide 1%/Timolol 0.5% in Patients With Open-Angle Glaucoma and Ocular Hypertension

NCT02325518 is registered in ClinicalTrials.gov with Alcon, a Novartis Company as lead sponsor.

NCT NCT02325518
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02325518 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Efficacy and Safety of Brinzolamide 1%/Timolol 0.5% Fixed Combination Versus Dorzolamide 1%/Timolol 0.5% in Patients With Open-Angle Glaucoma and Ocular Hypertension
Lead sponsor
Alcon, a Novartis Company
Phase
Phase 4
Overall status
Completed
Start date
December 31, 2014
Completion date
December 31, 2015
Enrollment
218 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ocular hypertension, open-angle glaucoma